Pamela Zeitlin
Concepts (471)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystic Fibrosis Transmembrane Conductance Regulator | 44 | 2022 | 302 | 7.700 |
Why?
| Cystic Fibrosis | 67 | 2022 | 1003 | 6.780 |
Why?
| Chlorides | 11 | 2020 | 142 | 1.710 |
Why?
| Chloride Channels | 11 | 2013 | 35 | 1.640 |
Why?
| Benzodioxoles | 6 | 2022 | 83 | 1.340 |
Why?
| Bronchi | 9 | 2012 | 253 | 1.190 |
Why?
| Epithelial Cells | 12 | 2021 | 995 | 1.150 |
Why?
| Mutation | 17 | 2022 | 3493 | 1.120 |
Why?
| Nasal Mucosa | 10 | 2020 | 97 | 1.000 |
Why?
| Interleukin-8 | 8 | 2017 | 256 | 0.940 |
Why?
| Indoles | 3 | 2022 | 318 | 0.860 |
Why?
| Phenylbutyrates | 4 | 2006 | 21 | 0.810 |
Why?
| Alprostadil | 2 | 2013 | 32 | 0.790 |
Why?
| Aminophenols | 6 | 2022 | 110 | 0.760 |
Why?
| Respiratory Mucosa | 7 | 2008 | 263 | 0.690 |
Why?
| Dependovirus | 5 | 2007 | 52 | 0.650 |
Why?
| Genetic Therapy | 8 | 2011 | 265 | 0.640 |
Why?
| Pseudomonas Infections | 5 | 2020 | 198 | 0.620 |
Why?
| Digitoxin | 1 | 2017 | 2 | 0.610 |
Why?
| Endoplasmic Reticulum | 8 | 2014 | 250 | 0.610 |
Why?
| Ubiquitin | 2 | 2014 | 68 | 0.580 |
Why?
| Epithelium | 4 | 2021 | 309 | 0.580 |
Why?
| Protein Processing, Post-Translational | 3 | 2014 | 421 | 0.570 |
Why?
| Proteomics | 3 | 2012 | 890 | 0.570 |
Why?
| Mucociliary Clearance | 3 | 2021 | 43 | 0.550 |
Why?
| Lung | 10 | 2022 | 3830 | 0.540 |
Why?
| Proteasome Endopeptidase Complex | 3 | 2014 | 140 | 0.540 |
Why?
| Sputum | 10 | 2020 | 293 | 0.530 |
Why?
| Sp1 Transcription Factor | 2 | 2006 | 23 | 0.510 |
Why?
| Anti-Inflammatory Agents | 2 | 2017 | 469 | 0.500 |
Why?
| Ion Transport | 5 | 2020 | 62 | 0.460 |
Why?
| Scorpion Venoms | 1 | 2013 | 2 | 0.460 |
Why?
| Pseudomonas aeruginosa | 4 | 2016 | 310 | 0.430 |
Why?
| Lysine | 1 | 2014 | 251 | 0.430 |
Why?
| Protein Array Analysis | 2 | 2012 | 64 | 0.430 |
Why?
| Gene Expression Regulation | 7 | 2009 | 2491 | 0.430 |
Why?
| Cell Line | 11 | 2014 | 2785 | 0.420 |
Why?
| Lubiprostone | 3 | 2022 | 9 | 0.410 |
Why?
| Humans | 78 | 2022 | 122796 | 0.410 |
Why?
| Inflammation | 3 | 2017 | 2598 | 0.390 |
Why?
| Quinolones | 4 | 2022 | 97 | 0.380 |
Why?
| NF-kappa B | 4 | 2009 | 676 | 0.380 |
Why?
| Respiratory System | 3 | 2022 | 144 | 0.380 |
Why?
| Ubiquitin Thiolesterase | 1 | 2010 | 38 | 0.360 |
Why?
| Caveolin 1 | 1 | 2009 | 23 | 0.350 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2006 | 852 | 0.340 |
Why?
| Aspergillus fumigatus | 1 | 2008 | 21 | 0.340 |
Why?
| Proteome | 4 | 2009 | 357 | 0.340 |
Why?
| Estrogen Antagonists | 1 | 2008 | 39 | 0.340 |
Why?
| Endocytosis | 1 | 2009 | 158 | 0.330 |
Why?
| Dinoprostone | 3 | 2022 | 193 | 0.320 |
Why?
| Trachea | 2 | 2008 | 238 | 0.320 |
Why?
| Tamoxifen | 1 | 2008 | 198 | 0.310 |
Why?
| Transcription Factor CHOP | 1 | 2007 | 29 | 0.310 |
Why?
| Calcium | 3 | 2008 | 1244 | 0.310 |
Why?
| Adolescent | 31 | 2020 | 18948 | 0.300 |
Why?
| Levofloxacin | 1 | 2007 | 22 | 0.300 |
Why?
| Ofloxacin | 1 | 2007 | 23 | 0.300 |
Why?
| Drugs, Investigational | 1 | 2007 | 31 | 0.300 |
Why?
| Adult | 34 | 2022 | 32385 | 0.300 |
Why?
| S-Nitrosoglutathione | 1 | 2006 | 6 | 0.290 |
Why?
| Mutant Proteins | 1 | 2007 | 101 | 0.290 |
Why?
| Heparan Sulfate Proteoglycans | 1 | 2006 | 22 | 0.280 |
Why?
| Nebulizers and Vaporizers | 2 | 2005 | 78 | 0.280 |
Why?
| Genetic Testing | 1 | 2008 | 400 | 0.280 |
Why?
| Sinusitis | 3 | 2020 | 162 | 0.270 |
Why?
| Membrane Potentials | 5 | 2013 | 273 | 0.270 |
Why?
| Chloride Channel Agonists | 2 | 2021 | 57 | 0.270 |
Why?
| Pneumonia, Bacterial | 1 | 2007 | 113 | 0.270 |
Why?
| Anti-Bacterial Agents | 6 | 2014 | 1562 | 0.270 |
Why?
| Water | 1 | 2008 | 433 | 0.270 |
Why?
| Estradiol | 1 | 2008 | 477 | 0.270 |
Why?
| Positive-Pressure Respiration | 1 | 2005 | 78 | 0.260 |
Why?
| Respiratory Function Tests | 6 | 2021 | 563 | 0.260 |
Why?
| Antibodies, Monoclonal | 1 | 2012 | 1306 | 0.260 |
Why?
| Homeostasis | 1 | 2008 | 596 | 0.260 |
Why?
| Aerosols | 2 | 2005 | 224 | 0.260 |
Why?
| Proteins | 3 | 2012 | 953 | 0.260 |
Why?
| Pyrrolidines | 2 | 2022 | 57 | 0.250 |
Why?
| Curcumin | 1 | 2004 | 36 | 0.240 |
Why?
| Flavonoids | 1 | 2004 | 73 | 0.240 |
Why?
| Female | 39 | 2020 | 63629 | 0.230 |
Why?
| Plicamycin | 1 | 2003 | 3 | 0.230 |
Why?
| Genetic Vectors | 5 | 2005 | 310 | 0.230 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1981 | 0.230 |
Why?
| Male | 37 | 2020 | 59639 | 0.230 |
Why?
| Immunity, Innate | 1 | 2009 | 762 | 0.230 |
Why?
| Membrane Proteins | 2 | 2006 | 1093 | 0.220 |
Why?
| Amniotic Fluid | 1 | 2003 | 69 | 0.220 |
Why?
| Forced Expiratory Volume | 6 | 2018 | 562 | 0.220 |
Why?
| Signal Transduction | 4 | 2022 | 4902 | 0.220 |
Why?
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 6 | 0.210 |
Why?
| Heterozygote | 2 | 2021 | 270 | 0.210 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 576 | 0.210 |
Why?
| Peptides, Cyclic | 1 | 2004 | 260 | 0.210 |
Why?
| Nanoparticles | 3 | 2011 | 329 | 0.210 |
Why?
| Prostaglandins | 1 | 2022 | 84 | 0.210 |
Why?
| Pyrazoles | 2 | 2022 | 366 | 0.210 |
Why?
| Biological Transport | 3 | 2008 | 392 | 0.200 |
Why?
| Pyridines | 2 | 2022 | 440 | 0.200 |
Why?
| Oxadiazoles | 2 | 2014 | 33 | 0.200 |
Why?
| Epithelial Sodium Channels | 1 | 2021 | 12 | 0.200 |
Why?
| Aminopyridines | 2 | 2021 | 86 | 0.190 |
Why?
| Quinolines | 1 | 2021 | 127 | 0.190 |
Why?
| Animals | 17 | 2022 | 34133 | 0.190 |
Why?
| Child | 25 | 2022 | 19561 | 0.190 |
Why?
| Antibodies, Viral | 2 | 2003 | 551 | 0.190 |
Why?
| Tobramycin | 4 | 2014 | 48 | 0.180 |
Why?
| Mice | 10 | 2022 | 15888 | 0.180 |
Why?
| Paranasal Sinuses | 1 | 2020 | 59 | 0.180 |
Why?
| Protein Transport | 3 | 2014 | 418 | 0.180 |
Why?
| Protein Structure, Tertiary | 2 | 2014 | 832 | 0.180 |
Why?
| Ergocalciferols | 2 | 2010 | 12 | 0.180 |
Why?
| Double-Blind Method | 6 | 2017 | 1711 | 0.180 |
Why?
| Ataxia Telangiectasia | 2 | 2010 | 17 | 0.170 |
Why?
| Cyclic AMP | 3 | 2008 | 260 | 0.170 |
Why?
| Immunoglobulin G | 1 | 2003 | 804 | 0.170 |
Why?
| Pulmonary Medicine | 2 | 2010 | 91 | 0.170 |
Why?
| Administration, Intranasal | 4 | 2007 | 74 | 0.170 |
Why?
| Genotype | 6 | 2021 | 1943 | 0.160 |
Why?
| Sweat | 4 | 2016 | 44 | 0.160 |
Why?
| Subcellular Fractions | 2 | 2008 | 86 | 0.160 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2020 | 207 | 0.160 |
Why?
| Administration, Inhalation | 8 | 2007 | 664 | 0.160 |
Why?
| Biomarkers | 4 | 2017 | 3662 | 0.160 |
Why?
| Vitamins | 2 | 2010 | 163 | 0.160 |
Why?
| Cell Membrane | 2 | 2014 | 741 | 0.150 |
Why?
| Respiratory Tract Infections | 3 | 2008 | 335 | 0.150 |
Why?
| Maryland | 1 | 2017 | 39 | 0.150 |
Why?
| Membrane Transport Modulators | 1 | 2017 | 7 | 0.150 |
Why?
| Aldehyde Oxidoreductases | 1 | 2017 | 31 | 0.150 |
Why?
| Vitamin D Deficiency | 2 | 2010 | 167 | 0.150 |
Why?
| Mice, Knockout | 3 | 2009 | 2737 | 0.140 |
Why?
| Lung Diseases | 1 | 2003 | 764 | 0.140 |
Why?
| Rifampin | 1 | 2017 | 71 | 0.140 |
Why?
| Leukocyte Count | 1 | 2017 | 309 | 0.140 |
Why?
| Adenosine Triphosphate | 2 | 2008 | 456 | 0.140 |
Why?
| Computational Biology | 2 | 2012 | 601 | 0.140 |
Why?
| DNA-Binding Proteins | 1 | 2003 | 1384 | 0.140 |
Why?
| Young Adult | 9 | 2020 | 11094 | 0.130 |
Why?
| Drug Combinations | 3 | 2022 | 292 | 0.130 |
Why?
| Child, Preschool | 11 | 2021 | 9755 | 0.130 |
Why?
| Gene Transfer Techniques | 3 | 2005 | 154 | 0.130 |
Why?
| Molecular Chaperones | 2 | 2008 | 177 | 0.130 |
Why?
| Transcription Factors | 1 | 2003 | 1616 | 0.130 |
Why?
| Cell Line, Transformed | 2 | 2006 | 140 | 0.120 |
Why?
| Drug Design | 2 | 2007 | 163 | 0.120 |
Why?
| Ubiquitination | 1 | 2014 | 91 | 0.120 |
Why?
| Protein Folding | 3 | 2004 | 255 | 0.120 |
Why?
| Sodium Chloride | 2 | 2005 | 154 | 0.120 |
Why?
| Aspergillosis, Allergic Bronchopulmonary | 2 | 2016 | 10 | 0.120 |
Why?
| Exocrine Pancreatic Insufficiency | 2 | 2016 | 20 | 0.120 |
Why?
| Amiloride | 2 | 2004 | 26 | 0.120 |
Why?
| Protein Stability | 1 | 2014 | 162 | 0.120 |
Why?
| Proteolysis | 1 | 2014 | 149 | 0.120 |
Why?
| Isoproterenol | 2 | 2004 | 127 | 0.120 |
Why?
| Cells, Cultured | 4 | 2021 | 4162 | 0.120 |
Why?
| Sleep | 1 | 2019 | 722 | 0.110 |
Why?
| Pediatrics | 3 | 2010 | 1009 | 0.110 |
Why?
| Mass Spectrometry | 2 | 2014 | 686 | 0.110 |
Why?
| Promoter Regions, Genetic | 3 | 2009 | 1188 | 0.110 |
Why?
| Phenotype | 6 | 2016 | 3070 | 0.110 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 3 | 2009 | 108 | 0.110 |
Why?
| Neutrophils | 2 | 2017 | 1246 | 0.110 |
Why?
| Colforsin | 2 | 2021 | 56 | 0.110 |
Why?
| Mice, Inbred C57BL | 3 | 2013 | 5020 | 0.100 |
Why?
| HEK293 Cells | 1 | 2014 | 651 | 0.100 |
Why?
| Expectorants | 1 | 2011 | 23 | 0.100 |
Why?
| Enzyme Inhibitors | 2 | 2006 | 836 | 0.100 |
Why?
| Staining and Labeling | 1 | 2012 | 159 | 0.100 |
Why?
| Down-Regulation | 3 | 2021 | 654 | 0.100 |
Why?
| Age Factors | 2 | 2017 | 3114 | 0.100 |
Why?
| Protein Conformation | 1 | 2014 | 851 | 0.100 |
Why?
| Transduction, Genetic | 1 | 2011 | 118 | 0.100 |
Why?
| Research Personnel | 2 | 2010 | 158 | 0.100 |
Why?
| RNA, Messenger | 3 | 2008 | 2720 | 0.100 |
Why?
| Vital Capacity | 1 | 2011 | 277 | 0.090 |
Why?
| Acetylcysteine | 1 | 2011 | 150 | 0.090 |
Why?
| Endopeptidases | 1 | 2010 | 73 | 0.090 |
Why?
| Cervix Mucus | 1 | 2009 | 2 | 0.090 |
Why?
| Microbiota | 1 | 2017 | 676 | 0.090 |
Why?
| Anhydrides | 1 | 2009 | 18 | 0.090 |
Why?
| Homozygote | 1 | 2010 | 192 | 0.090 |
Why?
| Membrane Microdomains | 1 | 2009 | 35 | 0.090 |
Why?
| Synaptosomes | 1 | 2009 | 12 | 0.090 |
Why?
| Posterior Horn Cells | 1 | 2009 | 4 | 0.090 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 101 | 0.090 |
Why?
| Models, Molecular | 1 | 2014 | 1443 | 0.090 |
Why?
| Spiperone | 1 | 2008 | 1 | 0.090 |
Why?
| Ribosomes | 1 | 2010 | 142 | 0.090 |
Why?
| Nutrition Assessment | 1 | 2009 | 78 | 0.080 |
Why?
| Models, Biological | 2 | 2007 | 1756 | 0.080 |
Why?
| Microscopy, Confocal | 1 | 2010 | 319 | 0.080 |
Why?
| Electric Conductivity | 1 | 2008 | 91 | 0.080 |
Why?
| Endoscopy | 1 | 2011 | 267 | 0.080 |
Why?
| Drug Carriers | 1 | 2009 | 118 | 0.080 |
Why?
| Respiratory System Agents | 1 | 2008 | 22 | 0.080 |
Why?
| Polyethylene Glycols | 2 | 2011 | 560 | 0.080 |
Why?
| Malnutrition | 1 | 2009 | 69 | 0.080 |
Why?
| Administration, Topical | 1 | 2008 | 154 | 0.080 |
Why?
| Rats | 3 | 2009 | 5426 | 0.080 |
Why?
| Biopsy | 1 | 2012 | 1090 | 0.080 |
Why?
| Codon, Terminator | 2 | 2007 | 21 | 0.080 |
Why?
| Fibrous Dysplasia, Polyostotic | 1 | 2007 | 7 | 0.080 |
Why?
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2007 | 8 | 0.080 |
Why?
| Statistics, Nonparametric | 2 | 2005 | 416 | 0.080 |
Why?
| Treatment Outcome | 9 | 2018 | 9692 | 0.080 |
Why?
| Adenoviridae | 2 | 2005 | 195 | 0.080 |
Why?
| Blotting, Western | 2 | 2007 | 1225 | 0.080 |
Why?
| Mice, Transgenic | 1 | 2013 | 2079 | 0.080 |
Why?
| Cytosol | 1 | 2008 | 229 | 0.080 |
Why?
| Aminoglycosides | 1 | 2007 | 15 | 0.080 |
Why?
| Chromatin Immunoprecipitation | 1 | 2007 | 139 | 0.070 |
Why?
| Ibuprofen | 1 | 2007 | 76 | 0.070 |
Why?
| Metabolic Clearance Rate | 1 | 2007 | 111 | 0.070 |
Why?
| Technology, Pharmaceutical | 1 | 2007 | 19 | 0.070 |
Why?
| Socioeconomic Factors | 1 | 2011 | 1158 | 0.070 |
Why?
| Mannose-Binding Lectin | 1 | 2006 | 26 | 0.070 |
Why?
| Cyclooxygenase 2 | 1 | 2007 | 172 | 0.070 |
Why?
| Nutritional Status | 1 | 2009 | 306 | 0.070 |
Why?
| HSP40 Heat-Shock Proteins | 1 | 2006 | 22 | 0.070 |
Why?
| Valosin Containing Protein | 1 | 2006 | 6 | 0.070 |
Why?
| Kidney Function Tests | 1 | 2007 | 166 | 0.070 |
Why?
| Polysaccharide-Lyases | 1 | 2006 | 13 | 0.070 |
Why?
| Airway Obstruction | 1 | 2008 | 182 | 0.070 |
Why?
| Tunicamycin | 1 | 2006 | 11 | 0.070 |
Why?
| DNA Primers | 1 | 2007 | 540 | 0.070 |
Why?
| Proteasome Inhibitors | 1 | 2006 | 46 | 0.070 |
Why?
| Asthma | 1 | 2019 | 2130 | 0.070 |
Why?
| DNA, Viral | 2 | 2005 | 358 | 0.070 |
Why?
| Chondroitin Sulfates | 1 | 2006 | 35 | 0.070 |
Why?
| CHO Cells | 1 | 2006 | 145 | 0.070 |
Why?
| Technetium Tc 99m Pentetate | 1 | 2005 | 7 | 0.070 |
Why?
| Gamma Cameras | 1 | 2005 | 7 | 0.070 |
Why?
| Cricetinae | 1 | 2006 | 269 | 0.070 |
Why?
| Luciferases | 2 | 2003 | 150 | 0.070 |
Why?
| Spinal Cord Injuries | 1 | 2009 | 184 | 0.070 |
Why?
| Glycosylation | 1 | 2006 | 134 | 0.070 |
Why?
| Radionuclide Imaging | 1 | 2005 | 134 | 0.070 |
Why?
| Nitric Oxide Synthase | 1 | 2006 | 227 | 0.070 |
Why?
| Glutamine | 1 | 2006 | 89 | 0.070 |
Why?
| Purinergic P2 Receptor Agonists | 1 | 2005 | 4 | 0.070 |
Why?
| Deoxycytosine Nucleotides | 1 | 2005 | 11 | 0.070 |
Why?
| Uridine | 1 | 2005 | 30 | 0.070 |
Why?
| Adenosine Triphosphatases | 1 | 2006 | 160 | 0.070 |
Why?
| Precision Medicine | 1 | 2009 | 371 | 0.070 |
Why?
| Chronic Disease | 2 | 2008 | 1645 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1003 | 0.060 |
Why?
| Nerve Tissue Proteins | 1 | 2009 | 557 | 0.060 |
Why?
| Tissue Distribution | 1 | 2005 | 339 | 0.060 |
Why?
| Acidosis | 1 | 2006 | 94 | 0.060 |
Why?
| Polymers | 1 | 2009 | 475 | 0.060 |
Why?
| Radiopharmaceuticals | 1 | 2005 | 196 | 0.060 |
Why?
| Nasal Polyps | 1 | 2004 | 42 | 0.060 |
Why?
| Gene Expression Profiling | 3 | 2006 | 1625 | 0.060 |
Why?
| Particle Size | 1 | 2005 | 344 | 0.060 |
Why?
| DNA | 1 | 2011 | 1401 | 0.060 |
Why?
| Dietary Supplements | 1 | 2008 | 473 | 0.060 |
Why?
| Inhalation Exposure | 1 | 2004 | 111 | 0.060 |
Why?
| Bronchial Provocation Tests | 1 | 2003 | 53 | 0.060 |
Why?
| Sp3 Transcription Factor | 1 | 2003 | 6 | 0.060 |
Why?
| Transfection | 1 | 2006 | 909 | 0.060 |
Why?
| Drug Administration Schedule | 4 | 2010 | 757 | 0.060 |
Why?
| Biomedical Research | 1 | 2010 | 630 | 0.060 |
Why?
| Base Sequence | 1 | 2007 | 2186 | 0.060 |
Why?
| Heat-Shock Proteins | 1 | 2004 | 129 | 0.060 |
Why?
| Recombinant Fusion Proteins | 2 | 2003 | 661 | 0.060 |
Why?
| Diuretics | 1 | 2003 | 78 | 0.060 |
Why?
| Single-Blind Method | 1 | 2004 | 275 | 0.060 |
Why?
| Protein Denaturation | 1 | 2003 | 74 | 0.060 |
Why?
| Sex Factors | 1 | 2008 | 1860 | 0.060 |
Why?
| RNA Interference | 1 | 2005 | 473 | 0.060 |
Why?
| Disease Progression | 3 | 2017 | 2546 | 0.060 |
Why?
| 5' Flanking Region | 1 | 2002 | 8 | 0.060 |
Why?
| Clinical Protocols | 1 | 2004 | 248 | 0.060 |
Why?
| Biological Transport, Active | 1 | 2002 | 74 | 0.050 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 2002 | 162 | 0.050 |
Why?
| Carrier State | 1 | 2002 | 57 | 0.050 |
Why?
| Dimethyl Sulfoxide | 1 | 2022 | 45 | 0.050 |
Why?
| Genetic Predisposition to Disease | 2 | 2008 | 2359 | 0.050 |
Why?
| Clinical Trials as Topic | 2 | 2004 | 985 | 0.050 |
Why?
| 1-Methyl-3-isobutylxanthine | 1 | 2021 | 25 | 0.050 |
Why?
| Anesthesiologists | 1 | 2022 | 15 | 0.050 |
Why?
| Patient Acceptance of Health Care | 1 | 2008 | 707 | 0.050 |
Why?
| Protein Isoforms | 1 | 2003 | 347 | 0.050 |
Why?
| Interleukin-13 | 1 | 2022 | 138 | 0.050 |
Why?
| NIH 3T3 Cells | 1 | 2021 | 141 | 0.050 |
Why?
| Forecasting | 1 | 2003 | 372 | 0.050 |
Why?
| Point Mutation | 1 | 2002 | 231 | 0.050 |
Why?
| Bronchodilator Agents | 1 | 2003 | 257 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1181 | 0.050 |
Why?
| Infant | 4 | 2020 | 8523 | 0.050 |
Why?
| Electrophysiology | 1 | 2021 | 205 | 0.050 |
Why?
| Occupational Exposure | 1 | 2004 | 298 | 0.050 |
Why?
| Interferon-gamma | 1 | 2005 | 747 | 0.050 |
Why?
| Drug Therapy, Combination | 1 | 2004 | 988 | 0.050 |
Why?
| Middle Aged | 8 | 2020 | 28563 | 0.050 |
Why?
| Codon, Nonsense | 2 | 2014 | 38 | 0.050 |
Why?
| Genetic Variation | 1 | 2006 | 952 | 0.050 |
Why?
| Nitric Oxide | 1 | 2006 | 884 | 0.050 |
Why?
| Up-Regulation | 1 | 2004 | 891 | 0.050 |
Why?
| Anti-Infective Agents | 1 | 2003 | 248 | 0.050 |
Why?
| Nasal Surgical Procedures | 1 | 2020 | 5 | 0.050 |
Why?
| Respiration | 1 | 2021 | 189 | 0.050 |
Why?
| Drug Monitoring | 2 | 2017 | 189 | 0.050 |
Why?
| Viscosity | 2 | 2011 | 90 | 0.050 |
Why?
| Patient Care Team | 1 | 2004 | 520 | 0.050 |
Why?
| Transcription, Genetic | 1 | 2006 | 1355 | 0.040 |
Why?
| Cell Survival | 1 | 2003 | 1075 | 0.040 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2017 | 633 | 0.040 |
Why?
| Albuterol | 1 | 2019 | 103 | 0.040 |
Why?
| Biological Products | 1 | 2021 | 166 | 0.040 |
Why?
| Retrospective Studies | 5 | 2020 | 13433 | 0.040 |
Why?
| Spirometry | 1 | 2019 | 291 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2003 | 1727 | 0.040 |
Why?
| Longitudinal Studies | 2 | 2018 | 2599 | 0.040 |
Why?
| Haplotypes | 1 | 2020 | 482 | 0.040 |
Why?
| Temperature | 1 | 2021 | 631 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2019 | 469 | 0.040 |
Why?
| Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.040 |
Why?
| Bacteria | 1 | 2003 | 772 | 0.040 |
Why?
| Biological Availability | 1 | 2017 | 129 | 0.040 |
Why?
| Biphenyl Compounds | 1 | 2017 | 59 | 0.040 |
Why?
| Seasons | 2 | 2010 | 468 | 0.040 |
Why?
| Fellowships and Scholarships | 2 | 2010 | 255 | 0.040 |
Why?
| DNA, Bacterial | 1 | 2017 | 324 | 0.040 |
Why?
| Pharmacogenetics | 1 | 2017 | 151 | 0.030 |
Why?
| Drug Interactions | 1 | 2017 | 356 | 0.030 |
Why?
| Cell Differentiation | 1 | 2003 | 1805 | 0.030 |
Why?
| 3' Untranslated Regions | 1 | 2016 | 147 | 0.030 |
Why?
| China | 1 | 2016 | 223 | 0.030 |
Why?
| Exons | 1 | 2016 | 310 | 0.030 |
Why?
| Case-Control Studies | 2 | 2017 | 3296 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 1018 | 0.030 |
Why?
| Bronchiectasis | 1 | 2016 | 102 | 0.030 |
Why?
| Colony Count, Microbial | 2 | 2005 | 124 | 0.030 |
Why?
| Antineoplastic Agents | 1 | 2005 | 1990 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2017 | 1531 | 0.030 |
Why?
| Time Factors | 3 | 2010 | 6682 | 0.030 |
Why?
| Polymerase Chain Reaction | 2 | 2007 | 1021 | 0.030 |
Why?
| Genes, Reporter | 2 | 2005 | 274 | 0.030 |
Why?
| Aging | 1 | 2003 | 1694 | 0.030 |
Why?
| Prevalence | 2 | 2010 | 2442 | 0.030 |
Why?
| Polylysine | 1 | 2011 | 19 | 0.030 |
Why?
| Biopolymers | 1 | 2011 | 28 | 0.030 |
Why?
| Mucins | 1 | 2011 | 64 | 0.020 |
Why?
| Diffusion | 1 | 2011 | 127 | 0.020 |
Why?
| Follow-Up Studies | 2 | 2010 | 4768 | 0.020 |
Why?
| Pregnancy | 1 | 2003 | 5854 | 0.020 |
Why?
| Plasmids | 1 | 2011 | 358 | 0.020 |
Why?
| CD4-CD8 Ratio | 1 | 2010 | 20 | 0.020 |
Why?
| 25-Hydroxyvitamin D 2 | 1 | 2010 | 7 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2020 | 2500 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2010 | 34 | 0.020 |
Why?
| Calcifediol | 1 | 2010 | 29 | 0.020 |
Why?
| Cross-Sectional Studies | 2 | 2011 | 4734 | 0.020 |
Why?
| Immunoassay | 1 | 2010 | 101 | 0.020 |
Why?
| Societies, Scientific | 1 | 2009 | 49 | 0.020 |
Why?
| Accreditation | 1 | 2010 | 96 | 0.020 |
Why?
| Indicator Dilution Techniques | 1 | 2009 | 12 | 0.020 |
Why?
| Adhesiveness | 1 | 2009 | 19 | 0.020 |
Why?
| Mice, Inbred CFTR | 1 | 2008 | 5 | 0.020 |
Why?
| Cohort Studies | 2 | 2011 | 5294 | 0.020 |
Why?
| Type C Phospholipases | 1 | 2008 | 76 | 0.020 |
Why?
| Baltimore | 1 | 2008 | 44 | 0.020 |
Why?
| Quality of Life | 1 | 2019 | 2457 | 0.020 |
Why?
| Biological Assay | 1 | 2008 | 123 | 0.020 |
Why?
| Small Molecule Libraries | 1 | 2008 | 83 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2010 | 363 | 0.020 |
Why?
| Cell Polarity | 1 | 2008 | 130 | 0.020 |
Why?
| Drug Discovery | 1 | 2008 | 128 | 0.020 |
Why?
| Hospitals, University | 1 | 2008 | 183 | 0.020 |
Why?
| Career Choice | 1 | 2009 | 206 | 0.020 |
Why?
| Placebos | 1 | 2007 | 204 | 0.020 |
Why?
| Models, Animal | 1 | 2009 | 373 | 0.020 |
Why?
| Solutions | 1 | 2007 | 154 | 0.020 |
Why?
| Gentamicins | 1 | 2007 | 45 | 0.020 |
Why?
| Receptors, Cell Surface | 1 | 2009 | 368 | 0.020 |
Why?
| Prospective Studies | 1 | 2018 | 6704 | 0.020 |
Why?
| Sulfur Radioisotopes | 1 | 2006 | 17 | 0.020 |
Why?
| Silver Staining | 1 | 2006 | 19 | 0.020 |
Why?
| Acute Kidney Injury | 1 | 2014 | 755 | 0.020 |
Why?
| Nutrition Surveys | 1 | 2008 | 240 | 0.020 |
Why?
| Dual Oxidases | 1 | 2006 | 1 | 0.020 |
Why?
| Flavoproteins | 1 | 2006 | 7 | 0.020 |
Why?
| Salivary Proteins and Peptides | 1 | 2006 | 10 | 0.020 |
Why?
| Peptide Mapping | 1 | 2006 | 65 | 0.020 |
Why?
| Energy Intake | 1 | 2009 | 453 | 0.020 |
Why?
| Comorbidity | 1 | 2011 | 1600 | 0.020 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 135 | 0.020 |
Why?
| Health Care Surveys | 1 | 2008 | 564 | 0.020 |
Why?
| Blotting, Southern | 1 | 2005 | 68 | 0.020 |
Why?
| Methionine | 1 | 2006 | 147 | 0.020 |
Why?
| Cell Membrane Permeability | 1 | 2006 | 89 | 0.020 |
Why?
| NADPH Oxidases | 1 | 2006 | 141 | 0.020 |
Why?
| Receptors, Purinergic P2Y2 | 1 | 2005 | 5 | 0.020 |
Why?
| Serum | 1 | 2006 | 65 | 0.020 |
Why?
| Helper Viruses | 1 | 2005 | 2 | 0.020 |
Why?
| Education, Medical, Graduate | 1 | 2010 | 432 | 0.020 |
Why?
| Societies, Medical | 1 | 2009 | 741 | 0.020 |
Why?
| Burkholderia | 1 | 2005 | 13 | 0.020 |
Why?
| Nasal Cavity | 1 | 2005 | 51 | 0.020 |
Why?
| Protein-Tyrosine Kinases | 1 | 2008 | 442 | 0.020 |
Why?
| Severity of Illness Index | 2 | 2004 | 2784 | 0.020 |
Why?
| Pancreatic Elastase | 1 | 2005 | 74 | 0.020 |
Why?
| Hemoptysis | 1 | 2005 | 32 | 0.020 |
Why?
| Peroxidase | 1 | 2005 | 182 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2006 | 547 | 0.020 |
Why?
| Reference Values | 1 | 2006 | 789 | 0.020 |
Why?
| Reagent Kits, Diagnostic | 1 | 2004 | 44 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2006 | 884 | 0.020 |
Why?
| Quality of Health Care | 1 | 2009 | 631 | 0.020 |
Why?
| Syndrome | 1 | 2004 | 363 | 0.010 |
Why?
| DNA, Recombinant | 1 | 2003 | 42 | 0.010 |
Why?
| Siblings | 1 | 2004 | 235 | 0.010 |
Why?
| Heating | 1 | 2003 | 18 | 0.010 |
Why?
| Treatment Failure | 1 | 2004 | 348 | 0.010 |
Why?
| Dyspnea | 1 | 2005 | 214 | 0.010 |
Why?
| Antibodies | 1 | 2006 | 400 | 0.010 |
Why?
| Saline Solution, Hypertonic | 1 | 2003 | 55 | 0.010 |
Why?
| Survivors | 1 | 2006 | 440 | 0.010 |
Why?
| Virus Shedding | 1 | 2003 | 47 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2009 | 2501 | 0.010 |
Why?
| Proportional Hazards Models | 1 | 2006 | 1184 | 0.010 |
Why?
| Survival Analysis | 1 | 2006 | 1325 | 0.010 |
Why?
| Hearing Disorders | 1 | 2002 | 10 | 0.010 |
Why?
| Probability | 1 | 2004 | 316 | 0.010 |
Why?
| Logistic Models | 1 | 2008 | 1995 | 0.010 |
Why?
| Audiometry | 1 | 2002 | 34 | 0.010 |
Why?
| United States | 2 | 2010 | 13272 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 16 | 0.010 |
Why?
| Oropharynx | 1 | 2002 | 41 | 0.010 |
Why?
| Viremia | 1 | 2003 | 133 | 0.010 |
Why?
| Confidence Intervals | 1 | 2003 | 339 | 0.010 |
Why?
| Infusions, Intravenous | 1 | 2003 | 396 | 0.010 |
Why?
| Oxidative Stress | 1 | 2009 | 1204 | 0.010 |
Why?
| Bronchoscopy | 1 | 2004 | 254 | 0.010 |
Why?
| Gene Rearrangement | 1 | 2002 | 141 | 0.010 |
Why?
| Recurrence | 1 | 2004 | 998 | 0.010 |
Why?
| Prognosis | 1 | 2010 | 3563 | 0.010 |
Why?
| Genetic Linkage | 1 | 2002 | 328 | 0.010 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 783 | 0.010 |
Why?
| Interleukins | 1 | 2003 | 246 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2005 | 1318 | 0.010 |
Why?
| DNA Mutational Analysis | 1 | 2002 | 390 | 0.010 |
Why?
| Body Mass Index | 1 | 2009 | 2144 | 0.010 |
Why?
| Pedigree | 1 | 2002 | 492 | 0.010 |
Why?
| Feasibility Studies | 1 | 2004 | 780 | 0.010 |
Why?
| Chi-Square Distribution | 1 | 2002 | 551 | 0.010 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 839 | 0.010 |
Why?
| Interleukin-6 | 1 | 2005 | 702 | 0.010 |
Why?
| Safety | 1 | 2002 | 307 | 0.010 |
Why?
| Creatinine | 1 | 2002 | 510 | 0.010 |
Why?
| Gene Expression | 1 | 2006 | 1506 | 0.010 |
Why?
| Analysis of Variance | 1 | 2004 | 1329 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2005 | 1855 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2002 | 904 | 0.010 |
Why?
| Kinetics | 1 | 2004 | 1658 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2008 | 2977 | 0.010 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 1213 | 0.010 |
Why?
| Apoptosis | 1 | 2009 | 2532 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2008 | 3799 | 0.010 |
Why?
| Kidney Diseases | 1 | 2002 | 446 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2010 | 4882 | 0.010 |
Why?
| Cytokines | 1 | 2005 | 1928 | 0.010 |
Why?
| Infant, Newborn | 1 | 2008 | 5430 | 0.010 |
Why?
| Hospitalization | 1 | 2005 | 1914 | 0.010 |
Why?
| Adenocarcinoma | 1 | 2002 | 837 | 0.010 |
Why?
| Risk Factors | 1 | 2008 | 9381 | 0.010 |
Why?
| Risk Assessment | 1 | 2004 | 3213 | 0.010 |
Why?
| Lung Neoplasms | 1 | 2002 | 2216 | 0.010 |
Why?
|
|
Zeitlin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|